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Abstract: The SARS-CoV-2 outbreak caused an unprecedented global public health threat,
having a high transmission rate with currently no drugs or vaccines approved. An alternative
powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2
main protease is essential for viral replication and an attractive drug target. In this study, we used
the virtual screening protocol with both long-range and short-range interactions to select candidate
SARS-CoV-2 main protease inhibitors. First, the Informational spectrum method applied for small
molecules was used for searching the Drugbank database and further followed by molecular docking.
After in silico screening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease
inhibitors that we propose for further experimental testing.
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1. Introduction
An outbreak of the novel coronavirus disease (COVID-19) in December of 2019 in Wuhan,
China, has spread promptly to more than 213 countries, with over 1,918,138 confirmed cases and
over 123,126 confirmed deaths worldwide as of 15 April 2020 [1]. The outbreak has been declared
a global pandemic by The World Health Organization (WHO) on 11 March 2020 [1]. It is uncertain
whether a COVID-19 pandemic will cause multiple concurrent epidemics over one to three years,
and SARS-CoV-2 may become an endemic virus globally [2]. Moreover, millions of people have been
disturbed as a result of mandatory isolations/quarantines and every part of society is severely affected,
with health care systems and economy adversely affected [3].
The outbreak caused by SARS-CoV-2 is an unprecedented global public health threat owing
to the high transmission rate of the virus, coupled with currently no drugs or vaccines approved.
In the pandemic setting with rapid virus transmission, new vaccine production is of exceptional
importance, besides much needed therapeutic, that are both expected to need months to years to
develop. The rapid response action to the emergent pandemic is repurposing of approved antiviral,
antimalarial, antiparasitic agents and those based on immunotherapy approaches to treat COVID-19,
with some clinical trials already started [4–6].
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An alternative efficient additional strategy to tackle COVID-19 is in silico drug repurposing
approaches. The main protease Mpro, also called 3CLpro, represents an attractive drug target due to its
essential role in the viral life cycle, crucial for viral replication. The pp1a and pp1ab, two overlapping
polyproteins, important for viral replication and transcription, are encoded by the SARS-CoV-2 replicase
gene [7,8]. The Mpro cleaves large polyprotein 1ab in at least 11 sites. The Mpro is highly conserved
across the Coronaviridae family and any mutation here can be disastrous for the virus [9,10]. As one
of the best-characterized drug targets among coronaviruses, in the absence of closely related human
homologues, the Mpro represents one of the most attractive SARS-CoV-2 drug targets. Since there is
no human protease with similar cleavage specificity, the inhibitors are expected to be nontoxic [11].
SARS-CoV-2 Mpro is active in a dimer form, consisting of two monomers arranged nearly perpendicular
to one another [11]. The dimerization is necessary for the Mpro enzymatic activity as the N-finger of
each of the two monomers interacts with Glu166 of the other monomer support the correct orientation
of the S1 pocket of the substrate binding site. Mpro active site comprises a catalytic dyad that consists of
the conserved residues H41 and C145 [9]. The available high-resolution experimental structure of the
main protease of SARS-CoV-2 was used in the current study as the target for molecular docking-based
virtual screening (VS) [7].
In this study, we used VS protocol with sequential filters, based on the both long-range and
short-range interactions, to select candidate SARS-CoV-2 Mpro inhibitors. First, the Informational
spectrum method applied for Small Molecules (ISM-SM) was used for searching Drugbank database [12],
and further was followed by molecular docking. By applying a new combo filter, we select 57 compounds
for further experimental testing. The use of such protocol is of great importance in case of drug
repurposing, for it can precisely determine protein domains where the possible binding site is placed,
and select small molecules that could specifically bind to those domains. In addition, due to the
simplicity of ISM-SM, a large number of compounds can be rapidly screened with little effort in data
preparation. In particular, due to COVID-19 fast expansion, a VS protocol that could bring promising
new drug candidates is of great importance.
2. Results
2.1. Informational Spectrum Method Analysis
In the present study, we have used the Informational spectrum method (ISM) for the
structure/function analysis of the highly conserved SARS-CoV-2 protein Mpro. According to the
previous studies, the informational characteristic of the protein, identified in the analysis, corresponds
to the protein key biological function. The informational spectrum (IS) of Mpro contains three
characteristic peaks at the frequencies F(0.1923), F(0.3183) and F(0.4414), shown in Figure 1. To find
the domains of a protein crucial for the information related to the three frequencies, Mpro was
computationally scanned. As a result of scanning with the ISM algorithm, with overlapping windows
of different lengths, we identified regions with the highest amplitudes at these frequencies. It was shown
that the regions, including residues 131–195, 151–183 and 72–136, are essential for the information
represented by the frequency F(0.1923), F(0.3183) and F(0.4414), respectively. Two dominant frequencies
of Mpro, F(0.1923) and F(0.3183), correspond to the catalytic domain of the enzyme, while F(0.4414)
to the allosteric domain (Figure 2). In the recent study, Ebselen has shown in-vitro Mpro inhibition
activity [7]. We calculated cross-spectrum (CS) for Mpro and Ebselen and found a dominant peak at
the F (0.1054) (Figure 3). Due to the importance, we additionally marked this frequency among three
others (Figure 1). This frequency was computationally mapped to domain 182–214, corresponding to
the allosteric domain. We further searched CS of Drugbank [12] candidates, with Mpro at the F(0.1923),
F(0.3183), F(0.4414) and F (0.1054), to find potential Mpro inhibitor candidates, with additional condition
that candidates’ IS contained main peaks on those values. With this search, we selected 57 candidate
drugs (Tables 1 and 2).
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Table 1. Docking scores of the compounds binding to the catalytic site.
Name Drugbank ID F Binding Energy (kcal/mol)
Mezlocillin DB00948 0.1923 −8.6
Camazepam DB01489 0.1923 −7.5
Spirapril DB01348 0.1923 −7.1
Bacampicillin DB01602 0.1923 −6.8
Bacitracin DB00626 0.3183 −6.6
Carbinoxamine DB00748 0.3183 −6.6
Paromomycin DB01421 0.1923 −6.5
Nifedipine DB01115 0.1923 −6.3
Gemfibrozil DB01241 0.1923 −5.9
Trimethaphan DB01116 0.1923 −5.6
Phensuximide DB00832 0.3183 −5.6
Nitrendipine DB01054 0.1923 −5.4
Paliperidone DB01267 0.1923 −5.4
Levetiracetam DB01202 0.1923 −5.2
Chlorambucil DB00291 0.1923 −5.2
Vitamin C DB00126 0.1923 −5.1
Tizanidine DB00697 0.1923 −5.0
Ifosfamide DB01181 0.1923 −4.9
Aminophenazone DB01424 0.1923 −4.6
Mecamylamine DB00657 0.1923 −4.3
Tazarotene DB00799 0.1923 −4.1
Table 2. Docking scores of the compounds binding to the allosteric site.
Name Drugbank ID F Binding Energy (kcal/mol)
Raltegravir DB06817 0.1054 −7.9
Rolitetracycline DB01301 0.4414 −7.6
Tolvaptan DB06212 0.1054 −7.3
Ciclesonide DB01410 0.1054 −7.2
Rescinnamine DB01180 0.4414 −7.2
Spectinomycin DB00919 0.1054 −6.8
Cefotiam DB00229 0.1054 −6.6
Azatadine DB00719 0.1054 −6.5
Flecainide DB01195 0.1054 −6.2
Pivmecillinam DB01605 0.1054 −6.2
Voriconazole DB00582 0.1054 −6.1
Ambenonium DB01122 0.1054 −5.9
Amitriptyline DB00321 0.1054 −5.9
Azapropazone DB07402 0.1054 −5.8
Miconazole DB01110 0.1054 −5.8
Clofedanol DB04837 0.1054 −5.7
Flutamide DB00499 0.1054 −5.7
Leflunomide DB01097 0.1054 −5.7
Tobramycin DB00684 0.1054 −5.7
Clevidipine DB04920 0.1054 −5.6
Imipramine DB00458 0.1054 −5.6
Kanamycin DB01172 0.1054 −5.6
Ciclopirox DB01188 0.1054 −5.5
Oseltamivir DB00198 0.1054 −5.5
Ospemifene DB04938 0.1054 −5.5
Trimipramine DB00726 0.1054 −5.5
Ebselen DB12610 0.1054 −5.3
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Table 2. Cont.
Name Drugbank ID F Binding Energy (kcal/mol)
Bepridil DB01244 0.1054 −5.1
Ethinamate DB01031 0.1054 −4.9
Propylthiouracil DB00550 0.1054 −4.5
l−Arginine DB00125 0.1054 −4.4
Isoflurophate DB00677 0.1054 −4.2
Ethanolamine Oleate DB06689 0.1054 −4.1
l−Carnitine DB00583 0.1054 −4.1
l−Lysine DB00123 0.1054 −4.0
Methoxyflurane DB01028 0.1054 −3.6
2.2. Molecular Docking
For further filtering of the selected compounds, we carried molecular docking into the catalytic
and allosteric domains of SARS-CoV-2 (Tables 1 and 2). The cut-off binding energy value for the
best candidates was set to −7.0 kcal/mol. From the initial docking, the best candidates were found
to be mezlocillin, camazepam and spirapril, targeting the catalytic site. Raltegravir, rolitetracycline,
tolvaptan, ciclesonide and rescinnamine were found targeting the allosteric domain. All compounds
have a better docking score than ebselen, which suggests that they could be potentially promising
inhibitors of SARS-CoV-2 Mpro. Because ebselen is an inhibitor of HIV-1 capsid C-terminal domain
dimerization [13], from this study is assumed that it analogously hinders Mpro dimerization.
Docking in the catalytic site showed that all candidates (Table 3, Figure 4, Figures S1–S3 in the
Supplementary Materials) interact with Cys 145 and His 41, which are essential for the catalytic activity
of Mpro [11]. Types of intermolecular interactions that candidates form with amino acid residues are
hydrogen bonds, aromatic π–π, alkyl–π, S–π and cation–π interactions.
From the docking results in the allosteric site (Table 4, Figure 5, Figures S4–S7 in the
Supplementary Materials), noticeable protein–ligand interactions are with Lys 5, which is next
to Arg 4, an essential residue for the dimerization process [11]. The other interacting residues (Lys 137,
Gly 138, Glu 290, Tyr 126 and Leu 286) are in accordance with those found from the biological assembly
in PDB 6LU7 (Table S1 in the Supplementary Materials).
In addition, by calculating CS of the drug, its main target and Mpro, we give a proof of the concept
of our method, implicating that the drug targets both proteins. For instance, in Figure S9 is presented
CS of mezlocillin, Mpro, and d-alanyl-d-alanine carboxypeptidase (Uniprot code Q75Y35), one of its
main targets. For all three entities, the common frequency value in CS is at F(0.1923). CS of docking top
hits, Mpro, and their main targets are presented in Figures S8–S14 (in the Supplementary Materials).
Table 3. Protein–ligand interactions in the catalytic site.
Residue Mezlocillin Camazepam Spirapril
THR27 X
HIS41 X X X
GLY143 X
SER144 X




MET49 X X X
MET165 X X
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3. Discussion
Current prevention and treatment options for SARS-CoV-2 infections are insufficient due to lack of
approved drug therapy or vaccines [10]. In a search for preventive and therapeutic options to counter
threats of pandemics, the fundamental problem is that drug development is a costly, time-consuming
and risky enterprise. Therefore, drug repurposing is a promising therapeutic strategy for many viral
diseases and the most realistic in the present pandemic. Various predictive in silico approaches have
been applied to identify drug repositioning opportunities against SARS-CoV-2 [10].
The manuscript’s originality lies in applying an innovative concept in selecting candidate molecules
for the treatment of SARS-CoV-2 infection, which includes molecular characteristics responsible for
long-range recognition and targeting between interacting biological molecules. The VS protocol
applied in this study is based on combined in silico approaches considering both short- and long-range
interactions between interacting molecules.
In this work, we have used the ISM for the structure/function analysis of the highly conserved
SARS-CoV-2 protein Mpro and identified the key informational characteristic of the protein,
which corresponds to the protein key biological function. The ISM was recently used for prediction
of potential receptor, natural reservoir, tropism, and therapeutic/vaccine target of COVID-19 [14].
In another recent study, ISM was used for the analysis of the COVID-19 Orf3b, suggesting that this
protein acts as a modulator of the interferon signaling network [15]. To select drug candidates for
SARS-CoV-2 Mpro inhibitor, further in this work, we used the VS protocol based on the application of
successive filters. First, the ISM-SM was used for the fast screening of large compound libraries through
candidate selection at a specific frequency value. Molecules were treated as quasi-linear entities,
analogous to peptides, and ISM was applied to predict potential candidates for the SARS-CoV-2 Mpro.
Previously this novel approach in bioinformatics treatment of small molecules was successfully used
for analyzing GPCR drugs of the Golden dataset [16] with amino acid sequences of corresponding
receptors. The essential information that can be extracted from protein–ligand CS spectra is the domain
of the binding site in the corresponding receptor [17]. As the second step of VS to meet short-range
compatibility, we used molecular docking.
The same drugs already selected in other studies as SARS-CoV-2 Mpro inhibitors represent
proof-of-concept for our novel in silico method. In this manuscript, several new SARS-CoV-2 Mpro
candidate inhibitors were also proposed. One of the best ranked allosteric inhibitors from our
computational study is ciclesonide. Another computational study also found ciclesonide as a potential
inhibitor of Mpro [18]. In in-vitro studies, ciclesonide showed good antiviral activity against SARS-CoV-2,
however against a different target [19]. The potential multitarget activity of ciclesonide may help
to overcome drug resistance in COVID-19. Additional favorable results were reported from studies
identifying that ciclesonide inhalant may improve the respiratory status in severe COVID-19-induced
pneumonia [20] and in cases of mild- to mid-stage COVID-19 [21]. Ciclesonide is a safe drug commonly
used for inhalation in premature babies and newborns, as well as the elderly. It is effective in controlling
chronic inflammation of the respiratory tract and the only steroid that showed anti-SARS-CoV-2
activity [21]. These studies gave rise to a recently initiated an open-labeled, randomized Phase 2
clinical trial to evaluate the antiviral effect of ciclesonide on the reduction of viral load in patients with
mild COVID-19 [22].
Raltegravir, the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor
and the best Mpro allosteric inhibitor according to our study, was among the 30 compounds,
with potential SARS-CoV-2 activity shown by a joint research team of the Shanghai Institute of Materia
Medica and Shanghai Tech University against SARS-CoV-2 from in silico and in-vitro analysis [23].
Another of the best ranked allosteric inhibitors from our computational study was rolitetracycline,
the first of the semi-synthetic tetracyclines. In recent molecular docking study it also showed the best
binding with the catalytic center of the SARS-CoV-2 Mpro through binding with CYS 145 and HIS
41 [24]. Tolvaptan is also in the group of potentially the best Mpro allosteric inhibitors. The efficacy
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and safety of tolvaptan therapy was reported in patients with the COVID-19-associated syndrome of
inappropriate antidiuretic hormone secretion [25,26].
In our work, mezlocillin was the best candidate for catalytic site inhibitor of Mpro. The same
result was also reported from another in silico study [27]. The second best candidate for catalytic
site inhibitor, camazepam, is a benzodiazepine. Although an anxiolytic, there have been earlier
reported antiviral activities of benzodiazepines [28]. According to our study, spirapril and ACE
inhibitors could be a promising catalytic site inhibitor candidate of SARS-CoV-2 Mpro. It was
proposed that ACE inhibitors could have both potentially harmful and beneficial effects on COVID-19.
Membrane-bound angiotensin-converting enzyme 2 (ACE2) participates in the entry of SARS-CoV-2
into human cells, and animal studies show that ACE inhibitors could upregulate ACE2 expression;
and on the other side, the beneficial effect can be expected with upregulated ACE2 converting
angiotensin II to angiotensin-(1–7), with potentially advantageous vasodilatory and anti-inflammatory
properties [29,30]. We can assume that ACE inhibitors through Mpro inhibition, in addition to the
already assumed theory of the advantageous effect of upregulated ACE2, could explain that treatment
with ACE-inhibitors is associated with less severe disease in SARS-CoV-2 infection [31].
A number of drugs selected in our study as repositioning candidates that potentially bind to
the catalytic site were also identified in other in silico studies that analyzed the same target. In the
molecular docking study, bacampicillin was among the best repurposed drugs against the main
protease of SARS-CoV-2 [32]. Carbinoxamine showed in another docking study potential activity
against SARS-CoV-2 Mpro [33]. In the docking study of FDA approved drugs against protease and
spike protein of COVID-19, paromomycin was found to have a strong binding affinity against both
Spike and Mpro of SARS-CoV-2 according to its glide score [34]. Phensuximide was found in molecular
docking simulations of FDA-approved small compounds associated with protection against COVID-19,
Mpro [35]. In VS-based study, magnesium ascorbate, a buffered (non-acidic) form of vitamin C,
was found to be the top lead compound among 106 nutraceuticals against SARS-CoV-2 s Mpro [36],
and tizanidine was amongst the 11 approved drugs predicted to show a high binding affinity in VS
study with Mpro [37].
The potential allosteric inhibitors found in our study were also selected as Mpro inhibitors in
several in silico studies. In the VS study, cefotiam was found among eight compounds potential
SARS-CoV-2 Mpro inhibitors [38]. In another docking study, voriconazole, tobramycin and kanamycin
showed potential activity against SARS-CoV-2 Mpro [33,37]. Ospemifene was among 51 hits selected
in silico against Mpro [39], and propylthiouracil was among the top 20 drugs showing the highest
docking score [40]. Besides, we found oseltamivir, the influenza neuraminidase inhibitor, to have
a higher docking score against SARS-CoV-2 Mpro than ebselen (Table 2). The use of oseltamivir
was already reported during the COVID-19 epidemic in China, either with or without antibiotics,
and clinical trials are ongoing with oseltamivir with multiple combinations with chloroquine and
favipiravir [41,42].
The benefit of the ISM-SM approach over other in silico approaches lies in its crucial ability to
determine the long-range molecular recognition between protein and ligand. Due to low demanding
data preparation, requiring only protein sequence and SMILES molecules notation of drug candidates,
it enables quick scanning of large molecular libraries.
The use of structural models of protein–drug complexes, combined with the ISM-SM approach,
can improve inhibitors against Mpro. Novel or modified ligands should maintain ISM spectrum features
of the known inhibitors by targeting a specific domain in Mpro (i.e., containing reported frequency
values in their CS). The next step, involving short-range interaction approaches, should be oriented not
only towards modifications that strengthen interactions with amino acid residues of the binding site.
The introduction of functional groups that interact with near residues, identified in specific domains
by ISM, should also be considered.
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Selected drugs from our computational study may represent an initial step for further experimental
investigations in a quest for safe, new treatments for COVID-19. The activity of inhibitors that we
propose should be further experimentally confirmed.
4. Materials and Methods
4.1. Informational Spectrum Method
In this work, we analyze the SARS-CoV-2 Mpro protein using the informational spectrum method
(ISM). A comprehensive explanation of the sequence analysis based on ISM is available elsewhere [43].
According to this approach, sequence (protein or DNA) is transformed into a signal by assignment of
numerical values of each element (amino acid or nucleotide). These values correspond to electron–ion
interaction potential (EIIP) [44], determining the electronic properties of amino acid/nucleotides,
which are essential for their intermolecular interactions. The EIIP descriptors are easily calculated





EIIP = 0.25Z∗ sin(1.04πZ∗)/2π, (2)
where i is type of the chemical element, Z is valence of the i-th chemical element, n is number of the i-th
chemical element atoms in the compound, m is number of types of chemical elements in the compound
and N is total number of atoms.
The EIIP signal is then transformed using fast Fourier transform (FFT) into information spectrum






N , n = 1, 2, . . . , N/2, (3)
where m is the summation index, x(m) is the m-th member of a given numerical “signal” series
(from a transformed, encoded primary protein sequence in our case), N is the total number of points in
this series), n is the number of a discrete frequency (ranging from 1 on up to N/2) in the DFT, X(n) are
the discrete Fourier transformation amplitude coefficients corresponding to each discrete frequency n
and 2π × (n/N) is the phase angle at each given m in the amino−acid series of the protein in question.
However, in the case of protein analysis, the relevant information is primarily presented in energy
density spectrum, which is defined as follows:
S(n) = X(n)X∗(n) =
∣∣∣X(n)∣∣∣2, n = 1, 2, . . . , N/2, (4)
By this, the virtual spectroscopy method is feasible to analyze protein sequences without any
previous experimental data functionally. Its extension for small molecules, ISM-SM, was developed
and published recently [17]. A small molecule is imported in SMILES notation and decoded by atomic
groups into an array of corresponding EIIP values. Using FFT, the corresponding IS of a small molecule
is computed. This spectrum is further multiplied by IS of the protein receptor to obtain a cross-spectrum
(CS). Cross-spectral function is the function which determines common frequency characteristics of
two signals. For discrete series it is defined as follows:
S(n) = X(n) ×Y(n)∗, n = 1, 2, . . . , N/2, (5)
where X(n) and DFT coefficients of the series x(m), and Y(n)* are complex conjugated DFT coefficients
of the series Y(m).
From common frequencies in CS, one can determine whether protein interacts with small molecules
and determine the corresponding binding region in the protein.
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4.2. Data Preparation
Protein sequences were downloaded from the UniProt database (https://www.uniprot.org/) with
the following accession numbers: Gaba alpha subunit, P14867 d-alanyl-d-alanine carboxypeptidase
Q75Y35, Angiotensin-converting enzyme P12821, HIV 1 Integrase Q7ZJM1, 30S ribosomal protein S9
P0A7X3, Vasopressin V2 receptor P30518. The FASTA COVID-19 Mpro sequence was downloaded from
RCSB, PDB ID 6LU7 and the corresponding IS was calculated. A set of 1490 approved Drugbank [12]
drugs with corresponding SMILES was subjected to IS and CS calculation with Mpro. All calculations
were carried out using our in-house software.
4.3. Molecular Docking
Molecular docking of selected candidates into the crystal structure of Mpro was carried out.
The receptor three-dimensional structure was downloaded from RCSB, PDB ID 6LU7 [7]. All ligands,
waters and ions were removed from PDB file. Two grid boxes with dimensions 24 × 24 × 24 Å were set
to span all amino acid residues interacting with co-crystallized inhibitor N3 in case of the catalytic site.
For the allosteric domain, it was set to span the residues interacting in the dimer interface. The (x, y, z)
centers of the grid boxes were (−11.775, 13.910, 66.706) for the catalytic site and (−22.521, 1.749, 50.782)
for the allosteric domain. Selected drugs from the previous step were converted from SMILES to 3D SDF
and further to PDB files, and protonated at physiological pH. Geometry optimization was carried out in
MOPAC 2016 [45] at PM7 level of theory [46]. Default software settings for hydrophobic and hydrophilic
terms in docking search function were used. Exhaustiveness was set to 50. Molecular docking was
carried out in Autodock Vina [47], implemented in VS software PyRx [48].
For intermolecular interactions identification, the following criteria were used: For hydrogen
bonds, as a maximum distance between the donor (D) and a hydrogen atom (H), D · · ·H, 3.4 Å was
used and angle D-H-A between 90◦ and 180◦; for a salt bridge maximum distance, D · · ·A, 4 Å was
used. For π–alkyl interactions, the maximum distance between the centroid of the aromatic ring
and the C-atom of the alkyl group was 4 Å and angle 45◦. Regarding S–π interactions, for edge-on
type, the maximum distance was 6 Å and angle 70◦; for face-on, 4.5 Å and 25◦. For π–π interactions,
the maximum distance between centroids was 6 Å, and values of theta and gamma angles were 50◦
and 35◦ for stacked and 30◦ and 55◦ for T-shaped conformation, respectively. For π–cation interactions,
the maximum distance between cation and centroid was 4 Å and angle 40◦.
Figures were made in BIOVIA Discovery Studio 2017 [49], Schrodinger Maestro 11.1 [50] and
Origin 9.0 software [51].
Supplementary Materials: The following are available online: Figure S1: Camazepam in the Mpro catalytic
site; Figure S2: Mezlocillin in the Mpro catalytic site; Figure S3: Spirapril in the Mpro catalytic site; Figure S4:
Raltegravir in the Mpro allosteric site; Figure S5: Rolitetracycline in the Mpro allosteric site; Figure S6: Tolvaptan in
the Mpro allosteric site; Figure S7: Rescinnamine in the Mpro allosteric site; Figure S8: CS of Mpro, Gaba alpha
subunit 1 and Camazepam; Figure S9: CS of Mpro, d−alanyl−d−alanine carboxypeptidase and Mezlocillin;
Figure S10: CS of Mpro, Angiotensin-converting enzyme and Spirapril; Figure S11: CS of Mpro, Integrase and
Raltegravir; Figure S12: CS of Mpro, 30S ribosomal protein S9 and Rolitetracycline; Figure S13: CS of Mpro,
Vasopressin V2 receptor and Tolvaptan; Figure S14: CS of Mpro, Angiotensin-converting enzyme and Rescinnamine,
Table S1: List of interacting residues in Mpro dimer in the biological assembly PDB ID 6LU7.
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